Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01042678 · ClinicalTrials.gov registry record · Phase 1
Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema
A Phase 1 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01042678: Clinical Trial Phase 1 study, sponsored by Allergan.
NCT01042678 is a Phase 1 study that was terminated before completion, run by Allergan. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01042678, a Phase 1 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of MP0112 (a novel, potentially long acting VEGF inhibitor) in patients with diabetic retinal edema.
Primary Outcome
Safety and tolerability was assessed by vital signs, clinical laboratory evaluations, ophthalmological examinations, intraocular pressure, the presence of anti-drug antibodies and the collection of adverse events. An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.
Interventions
- BIOLOGICAL MP0112
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Why NCT01042678 stopped before completion
NCT01042678 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which MP0112 is the first listed.
NCT01042678 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01042678 about?
NCT01042678 is a clinical study titled "Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema". The purpose of this study is to assess the safety and tolerability of MP0112 (a novel, potentially long acting VEGF inhibitor) in patients with diabetic retinal edema.
What is the current status of trial NCT01042678?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-02. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01042678?
The interventions under investigation include: MP0112 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01042678?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01042678's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia